The pharmaceutical sector has been vibrant, innovation-driven and successful. A confluence of spectacular advances in chemistry, molecular biology, and genomics led to the discovery of numerous compounds. Significant efforts are aimed at improving the integration of discovery technologies, chemical outsourcing formulations, and refined deployment of information technologies. Industry has undergone unprecedented changes due to mergers, acquisitions, drugs losing patent protection: a paucity of new drugs created an “innovation deficit”. Rapidly increasing pace of regulatory reform allied with the necessity of effecting drastic cost-reductions have resulted in strategic paradigm shifts We review herein, how our serendipitous observations led to discovery of NCEs and explore how mutual benefits can be obtained by sophisticated technology, strategic collaborations, and refined logistics. Our proprietary in vitro chemical technology (“synthetic livers”) allows us to mimic the in vivo metabolism of chemical entities used in pharmaceuticals, cosmetics, polymers, agricultural and synthetic dyes. Our catalysts enable prediction of metabolism patterns, pathways and profiles and introduces a new paradigm for drug discovery and mimicking drug-drug interactions for clinical diagnostics. The current trends in entrepreneurship in the evolving chemical workforce will be highlighted and the wisdom of successful chemists will be discussed.

Building businesses based on integration of basic and applied research: Value creation and new opportunities for chemists

ACS Spring Meeting 2021

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.